This combination was created to benefit from neprilysin inhibitor (NEPI) and angiotensin receptor blockers (ARB) by decreasing the risk of angioedema induced by angiotensin-converting enzyme inhibitors (ACEI) (Akbar et al., 2020). The gene discussed is MME; the disease is angioedema.